MedTrace Logo

Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)

NCT00804128 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2024-01-19

No results posted yet for this study

Summary

\*REFERRALS TO THIS TRIAL MUST BE THROUGH BREAST CARE CLINICIANS ONLY\*

RATIONALE: Diagnostic procedures, such as contrast-enhanced MRI, may help find and diagnose ductal carcinoma in situ.

PURPOSE: This study is to develop and refine magnetic resonance (MR) imaging methods for pre-operative staging of ductal carcinoma in situ, a pre-invasive form of breast cancer, and atypical ductal hyperplasia, a risk factor for developing cancer.

Conditions

Interventions

PROCEDURE

Magnetic Resonance Imaging (MRI)

Undergo MRI

DRUG

Gadavist

Gadavist injection is a paramagnetic macrocyclic contrast agent administered for magnetic resonance imaging

Sponsors & Collaborators

Principal Investigators

  • Nola M. Hylton, PhD · University of California, San Francisco

  • Bonnie Joe, MD, PhD · University of California, San Francisco

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-01
Primary Completion
2024-01-05
Completion
2024-01-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00804128 on ClinicalTrials.gov